ReviewNutrients2026
Dietary and Nutritional Considerations for Metabolic Dysfunction-Associated Steatotic Liver Disease in Psoriasis and Hidradenitis Suppurativa: A Narrative Review.
Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognised in patients with chronic inflammatory skin disease, particularly psoriasis, for which epidemiological evidence of increased MASLD prevalence is relatively strong; corresponding data in hidradenitis suppurativa (HS) remain more limited. This narrative review examines the epidemiological and biological links between psoriasis, HS and MASLD, and evaluates dietary and nutritional strategies relevant to their multidisciplinary management. Particular emphasis is placed on distinguishing direct evidence in patients with concomitant inflammatory skin disease and MASLD from evidence derived from dermatology cohorts without liver-specific outcomes and from general MASLD populations. Mediterranean-style dietary patterns, energy restriction and weight loss, improved diet quality, and reduced intake of ultra-processed foods and added sugars are supported principally by MASLD and cardiometabolic data, with more limited direct evidence in psoriasis or HS. The review also discusses nutritional considerations during incretin-based therapy, including reduced food intake, preservation of lean mass, micronutrient adequacy and gastrointestinal adverse effects, while highlighting areas in which recommendations remain extrapolated or expert-derived. For dermatologists, the practical emphasis is on recognition of metabolic risk, general dietary counselling and appropriate multidisciplinary referral. Overall, nutritional management is an important component of MASLD care, but dedicated intervention studies in patients with concomitant psoriasis or HS remain a major evidence gap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.